06.17.15
Scottsdale, Ariz.-based CyMedica Orthopedics Inc. has closed an extension to its series A financing. The round was led by investors Research Corporation Technologies Inc., a Tucson, Ariz.-based venture capital firm, and California Technology Ventures LLC, a Pasadena, Calif.-based venture capital fund. The financing also included participation from existing investor Aphelion Capital (Mill Valley, Calif.) and the founding group of investors.
The company’s first product, the Cymedica QB1 system for the treatment of quadriceps muscle atrophy, has received 510(k) clearance and was launched in April. The system is meant to allow surgeons to combine three best-in-class products (a postoperative knee brace, a form-fitting conductive garment, and a user-friendly neuromuscular electrical stimulation control interface), allowing orthopedic surgeons to treat every patient like a professional athlete. The QB1 technology uses a closed-loop power control system delivering high intensity electrical muscle stimulation to patients while maintaining comfort. The device is hoped to simplify the delivery of at-home neuromuscular electrical stimulation treatment and encourage patient compliance.
“This successful round of financing will enable us to expand our sales and distribution footprint and further support the continued rollout of our QB1 system,” said Rob Morocco, president and CEO of CyMedica Orthopedics. “We’re excited to have the backing of an excellent group of strategic investors supporting us in building the organization and expanding the applications of our platform technology.”
CyMedica Orthopedics makes products that target muscle atrophy using its patented platform technology.
The company’s first product, the Cymedica QB1 system for the treatment of quadriceps muscle atrophy, has received 510(k) clearance and was launched in April. The system is meant to allow surgeons to combine three best-in-class products (a postoperative knee brace, a form-fitting conductive garment, and a user-friendly neuromuscular electrical stimulation control interface), allowing orthopedic surgeons to treat every patient like a professional athlete. The QB1 technology uses a closed-loop power control system delivering high intensity electrical muscle stimulation to patients while maintaining comfort. The device is hoped to simplify the delivery of at-home neuromuscular electrical stimulation treatment and encourage patient compliance.
“This successful round of financing will enable us to expand our sales and distribution footprint and further support the continued rollout of our QB1 system,” said Rob Morocco, president and CEO of CyMedica Orthopedics. “We’re excited to have the backing of an excellent group of strategic investors supporting us in building the organization and expanding the applications of our platform technology.”
CyMedica Orthopedics makes products that target muscle atrophy using its patented platform technology.